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NIPT uptake in the general population has been rapidly increasing despite relatively 
low incidences of fetal aneuploidy in this cohort. This is further complicated by the 
inclusion of microdeletion syndromes, which have even lower positive predictive 
values (PPVs). This retrospective pilot study examines the performance and impact 
on patient decision making of a SNP-based NIPT in a general population cohort. A 
chart review was conducted of NIPT results from January 1, 2014 to August 24, 
2015 at Montefiore Medical Center in the Bronx, NY. NIPT results were obtained for 
3,747 samples. 1.33% of reports were high risk. One third of all high risk reports 
indicated a high risk for 22q11.2 deletion syndrome. 37.5% of women with high risk 
for 22q11.2DS elected diagnostic testing. None of the 5 whose diagnostic testing 
results were available were found to have an affected pregnancy. The total number 
of no call samples was 282 (7.53%). Cases in which the initial draw failed with low 
fetal fraction as a contributing factor had a redraw success rate of 28.75%. 
Differences in population characteristics can significantly impact the clinical utility of 
NIPT. The addition of conditions such as 22q11.2DS to NIPT panels will increase 
genetic counseling burden and complicate patient decision making. Overall, patients 
need to be aware that NIPT does not replace diagnostic testing, that PPVs differ 
significantly for microdeletion syndromes, and that redraw success is variable. 
 
MeSH Keywords: prenatal diagnosis, fetal aneuploidy, cell-free DNA, noninvasive 







Non-invasive prenatal testing (NIPT) has been available clinically since 2011 
and has become a popular alternative or addition to traditional serum screening for 
chromosomal aneuploidy, boasting close to 100% accuracy and very high positive 
predictive values (PPV) for high-risk pregnant women (Taylor-Phillips et al., 2016). 
Although clinical validity and utility have been studied in the high risk population, 
there is less information available on utility for low risk women, despite increasing 
use of NIPT in the general obstetrical population. Some clinicians are hesitant to 
offer NIPT to a cohort with a relatively low incidence of fetal aneuploidy, as the test 
will have lower PPVs.  
The recent inclusion of microdeletion syndromes on the NIPT panels offered 
by several companies has further complicated the use of this screen. Unlike the 
trisomies traditionally analyzed on NIPT, microdeletion syndromes are not 
associated with advanced maternal age. Therefore, microdeletion screening by NIPT 
is equally relevant for women under 35, who are considered to be at low risk to have 
a pregnancy affected with an aneuploidy. For both low and high risk populations, the 
low PPVs of microdeletion syndromes will lead to an increasing number of false 
positive results as more women are tested (Wapner et al., 2015). The low PPVs of 
microdeletion syndromes on NIPT is especially concerning as a few patients have 
been reported to have elected to terminate based solely on a positive NIPT result, 
without confirmatory testing (Weaver, 2013; Dobson et al., 2016). 
This retrospective pilot study will explore the utility of NIPT including the 




population cohort, as measured by the effect on patient decision making. 22q11.2DS 
is the most common microdeletion syndrome in the general population (1 in 4,000) 
and clinically significant in that many affected individuals are born with serious 
congenital abnormalities, with most having mild to moderate cognitive impairments 
as well as a risk of psychiatric illness and immune dysfunction (Hacijhamdioglu et 
al., 2015). Early diagnosis is important as prompt treatment may improve prognoses 
(Botto et al., 2003). 
Another aspect of NIPT that may affect the clinical utility of this screening tool 
in the general population is the impact of fetal fraction on test accuracy, including 
false positive and false negative rates. Fetal fraction is the relative amount of cell-
free fetal DNA (cffDNA) to cell-free maternal DNA in maternal plasma. Low fetal 
fraction can affect the sensitivity and specificity of NIPT and decrease the likelihood 
that a result is obtainable on redraw (Levy et al., 2013). This characteristic of the 
screen may be especially important to consider in populations with high rates of 
obesity, since higher maternal weights are associated with lower fetal fractions 
(Rava et al., 2013; Ashoor et al., 2013; Kinnings et al., 2015). Thus, this pilot study 
will also examine the frequency of no call results with low fetal fraction and how this 















Accuracy of NIPT and Discordant Test Results 
Since the introduction of NIPT in the clinical setting in 2011, many groups 
have studied the validity of this screening modality in comparison to the pre-existing 
standard of care. Reported sensitivities and specificities of NIPT vary somewhat 
between different versions of the technology and different study populations, but 
overall NIPT has been shown to have much higher sensitivity and specificity than 
traditional screening methods (Bianchi et al., 2014). NIPT is known to be most 
accurate in detecting trisomy 21, with sensitivity and specificity reported to range 
from 98-100% (Bianchi et al., 2012; Palomaki et al., 2011). Somewhat lower 
accuracy has been described for trisomy 18, trisomy 13, and sex chromosome 
aneuploidies, but many investigators have shown sensitivities for these conditions to 
be higher than 90% and specificities for all conditions to be greater than 99% 
(Pergament et al., 2014; Nicolaides et al., 2014; Samango-Sprouse et al., 2013). A 
recent meta-analysis of the literature reported sensitivities of 99% for trisomy 21, 
96.8% for trisomy 18, 92.1% for trisomy 13, 88.6% for monosomy X, and 93.8% for 
all other sex chromosome aneuploidies with specificity greater than 99% and false 
positive rates at 0.2% or below for all aneuploidies (Gil et al., 2014). 
While the accuracy of NIPT offers an advantage over previous standard 
obstetrical screening, false positive and negative results continue to be a concern. 
This is an issue that has been garnering attention as NIPT is offered to increasing 
numbers of women, many of whom do not receive adequate information about the 




validated high rates of sensitivity and specificity in both high and low risk cohorts, but 
few review positive predictive values (Dan et al., 2012; Pergament et al., 2014). This 
is of importance for clinicians as NIPT is being offered in increasing numbers to 
women in the low risk population, a group where PPVs are predicted to be lower 
based on a reduced baseline incidence of aneuploidy (ACOG, 2015; Gregg et al., 
2013). 
In a recent study comparing NIPT results to pregnancy outcomes in over 
100,000 cases in China, the authors evaluated the overall efficacy of the screen to 
detect trisomies 21, 18, and 13. The study was performed on general population 
samples that did not categorize women by their risk status. Only 9 false negative 
results were observed. PPV was determined to be 92.19% for trisomy 21, 76.61% 
for trisomy 18, and 32.84% for trisomy 13 based on a total of 157 false positive 
results (Zhang et al., 2015). 
In a study sponsored by Natera of close to 30,000 high and low risk cases, 
PPVs were reported to be 90.9% for trisomy 21, 93.1% for trisomy 18, 38.1% for 
trisomy 13 and 50% for monosomy X, based on cases with cytogenetic confirmation 
(Dar et al., 2014). Another study looking specifically at sex chromosome 
aneuploidies obtained a similar PPV of 54.17% (Yao et al., 2014). Positive predictive 
values mentioned in other studies vary widely and tend to have large confidence 
intervals due to smaller sample sizes (Bianchi et al., 2014; Neufeld-Kaiser et al., 
2015). 
Several studies have been done in follow up to discordant NIPT results in 




positive results. Conditions known to be responsible for causing discordant results 
are mosaicism, presence of a vanishing twin, maternal chromosome abnormalities, 
maternal malignancy, and technical errors (Grati et al., 2014). 
Researchers have attempted to determine if there are underlying factors that 
can contribute to a false positive test result. Clinicians in New Jersey described three 
cases of false positive NIPT results for fetal sex chromosome aneuploidies 
(McNamara et al., 2015). In two of the cases, the mothers were found to be mosaic 
for Turner syndrome and in the third case the mother was known to be 47,XXX. In 
another study, investigators hypothesized that two false positive trisomy 18 results 
were actually due to benign maternal partial duplications of chromosome 18 (Snyder 
et al., 2015). Maternal cancer, usually appearing on NIPT analysis as multiple fetal 
aneuploidies, has also been implicated as a cause of discordant results (Bianchi et 
al., 2015). 
In addition to aneuploidy, some labs have expanded NIPT to offer screening 
for common microdeletion syndromes. These include DiGeorge or 22q11.2 deletion, 
Cri-du-chat, Prader-Willi/Angelman, 1p36 deletion, and Wolf-Hirschhorn syndromes. 
Offerings vary from laboratory to laboratory. Although approximately 1.7% 
pregnancies have been shown to be affected by a clinically relevant microdeletion or 
microduplication (Wapner et al., 2012), the incidence of any one of these syndromes 
is very low in the general population, detection rates are lower relative to 
aneuploidies, and some laboratories leave these conditions off of reports unless the 




One study attempting to model the performance of NIPT (SNP-based) in 
detecting microdeletion syndromes showed a detection rate of 83.3% for 22q11.2DS 
and 45.5% overall (Wapner et al., 2015) but PPVs ranged from 3.8%-17% based on 
the incidence of the condition being analyzed. Of note, researchers in this study 
used artificial mixtures of DNA from mothers, affected children, and microdeletion 
cell lines in order to generate sufficient numbers of positive results to establish 
predicted detection rates. 
In February of this year, researchers from Natera published a paper that 
looked at the efficacy of SNP-based NIPT testing for 22q11.2DS in a clinical setting 
(Gross et al., 2016). They examined 21,948 samples, of which 97 screened positive 
for 22q11.2DS. PPV was calculated to be 18% overall. For pregnancies considered 
to be high risk for the microdeletion before undergoing NIPT, or those that had 
associated ultrasound findings, the PPV was 89.9% (8/9) and for those considered 
to be low risk, or those without associated ultrasound findings, the PPV was 5.1% 
(2/39).  Although an 18% PPV is higher than those reported in previous studies, the 
authors of this study acknowledge that some women may have been offered NIPT 
only after an associated ultrasound finding was discovered, which could potentially 
have skewed the data in favor of true positive results. 
Impact of NIPT Results on Patient Decision-Making 
While strict practice guidelines regarding the use of NIPT as a prenatal 
screening tool have yet to be published, the American College of Medical Genetics 
(2013), National Society of Genetic Counselors (2013), and American College of 




Each of the position statements raise concerns regarding the cost-effectiveness and 
clinical utility of NIPT in the general population. They also emphasize the need for 
pre and post-test counseling to ensure that women understand the accuracy and 
limitations of NIPT as a screening tool. The authors reiterate that NIPT is a 
screening tool that should be considered in conjunction with ultrasound findings and 
that diagnostic testing via CVS or amniocentesis should always be offered in the 
case of positive results before decisions are made about pregnancy management. 
 ACOG (2015) and NSGC concur in their opinion that conventional screening 
methods should still be used as the standard of care in the low risk population. 
(Devers et al., 2013) 
The reduced risk of NIPT relative to invasive diagnostic prenatal procedures 
seems to be increasing rates of NIPT uptake and decreasing the number of 
diagnostic procedures performed (Tiller et al., 2015). A retrospective study by Wax 
et al. found significantly increased rates of genetic counseling as well as decreased 
rates of diagnostic procedures (2015). Chetty et al. suggest that some women use 
NIPT rather than diagnostic testing after a positive first trimester screen (2013).  
 Multiple studies have described a decrease in the rates of CVS and 
amniocentesis after the introduction of NIPT (Larion et al., 2014; Tiller et al., 2015).. 
Although the sample size was small (n = 200), Tiller reported that 8% of women 
underwent a diagnostic procedure after a normal NIPT result. Reasons given by 
women for electing CVS or amniocentesis varied, including continued maternal 
anxiety about a chromosome abnormality, ultrasound findings, and positive 




showed similar rates of uptake of invasive diagnostic procedures after a normal 
NIPT result, stating that 7% of women had amniocentesis or CVS subsequent to a 
negative noninvasive prenatal test compared to 60% of women who had a positive 
NIPT result (Pettit et al., 2014). 
Concerns have been raised over women choosing to terminate based on 
NIPT results without confirming aneuploidy via diagnostic testing and karyotype 
analysis. A cohort of high risk patients was studied to determine uptake of diagnostic 
testing and termination rates after positive NIPT results (Dobson et al., 2016). They 
found that 64% of women underwent diagnostic testing after a high risk result and 
67% of women overall chose to terminate after a positive result. Significantly, of the 
67% of women who chose to terminate, 11 chose to do so without pursuing 
diagnostic testing. Of those who chose to terminate without confirmation of the NIPT 
result, 82% (9/11) had ultrasound findings. Additionally, 36% (4/11) of women who 
chose to terminate without diagnostic testing had not received post-test counseling 
(Dobson et al., 2016). Natera’s 2016 study focusing on women who received high 
risk results for 22q11.2DS found that 50.5% (n=48) of women with these results 
elected diagnostic testing. Of the 11 women who were found to have true positive 
results on diagnostic testing, 2 elected termination.  
Fetal Fraction in NIPT 
Fetal fraction is the measurement of cell-free fetal DNA in relation to 
circulating cell-free maternal DNA in maternal plasma. It is used as a quality control 
measurement during NIPT to ensure that there is a sufficient amount of cffDNA 




Researchers are working to understand the factors that influence fetal fraction in an 
effort to reduce the number of samples in which results cannot be returned as well 
as to optimize testing algorithms. The cutoff for fetal fraction differs between 
laboratories, but is generally around 4%. The average fetal fraction at 10-13 weeks, 
or when NIPT is most often performed, is about 10-13% (Ashoor et al., 2013; 
Bianchi et al., 2014). 
A 2013 study by Ariosa Diagnostics looked at over 22,000 pregnancies and 
examined the dynamics of fetal fraction throughout gestation (Wang et al., 2013). 
They found that 1.9% of samples drawn after 10 weeks gestation failed to produce 
results because they had less than 4% fetal fraction, and that sample failure was 
more likely to occur in samples drawn at earlier gestations and in individuals with 
higher maternal weight. Additionally, they concluded that on average, fetal fraction 
increases 0.1% per week between 10 and 21 weeks gestation and 1% per week 
after 21 weeks. The inverse association between fetal fraction and maternal weight 
may be due to a dilution effect from an increased circulatory volume (Haghiac et al., 
2012). It is also hypothesized that maternal weight causes a decrease in fetal 
fraction because adipose tissue turnover is known to be accelerated in obese 
women leading to an increase in circulation of maternal cell free DNA (Haghiac et 
al., 2012). Other studies have subsequently confirmed the relationships between 
fetal fraction and maternal weight as well as gestational age (Rava et al., 2013; 
Ashoor et al., 2013; Kinnings et al., 2015).  
In a large retrospective study of over 23,000 NIPT samples taken from 




maternal and fetal characteristics on the amount of circulating cell free fetal DNA 
(Zhou et al., 2015). They considered pre-gestational diabetes, hyperthyroidism, pre-
existing maternal hypertension, maternal BMI, hepatitis B status, fetal aneuploidies 
and twin versus singleton pregnancies. They concluded that trisomy 21 and lower 
maternal body mass index (BMI) were associated with higher fetal fraction, while 
trisomy 18 and pre-existing maternal hypertension were associated with lower than 
average fetal fraction. Other factors did not show significant correlations. 
Another study examining only the relationship between fetal aneuploidy and 
fetal fraction looked at fetal fractions in women 10-23 weeks gestation to determine if 
fetal karyotype affected cffDNA and maternal cell-free DNA ratios. They found that 
trisomy 21 pregnancies had higher than average fetal fractions, while trisomy 18, 
trisomy 13, and monosomy X pregnancies had lower than average fetal fractions 
(Rava et al., 2013). Pergament et al.’s reported in 2014 that in cases of fetal 
aneuploidy, results were not returned 16% of the time due to low fetal fraction, as 
opposed to approximately 5% of cases without aneuploidy. 
Beyond maternal characteristics and fetal aneuploidy, researchers have 
begun to explore less static factors in an effort to reduce the rate at which individuals 
will fail to receive an NIPT result due to low fetal fraction.  Early studies have 
indicated a potential relationship between low fetal fraction and fetal characteristics 
such as crown-rump length, maternal ethnicity and the level of other pregnancy-
related analytes such as pregnancy associated plasma protein A (Papp-A) (Ashoor 




other complications of pregnancy have raised the question of whether or not low 
fetal fraction is itself grounds for concern.   
In addition to the characteristics examined by Ashoor’s group, one study 
looked at the effect of exercise on fetal fraction. They demonstrated that fetal 
fraction is lower when maternal blood samples are taken immediately after physical 
activity, but then return to normal by 30 minutes post-exercise (Schlütter et al., 
2014). 
When NIPT fails with low fetal fraction as a contributing factor, laboratories 
often request an additional sample from the patient to rerun the test. Rescue rates of 
samples with insufficient fetal fraction at the first blood draw were reported by one 
group to be higher than 50%, even with the second blood draw taking place within 
10 days of the first (Kinnings et al., 2015). Similar results were also seen by the 
group from Ariosa, who showed a 56% recovery rate redraw at an average of 3-4 




This study is a retrospective chart review of patients at Montefiore Medical 
Center in the Bronx, NY. The study was approved by the Albert Einstein College of 
Medicine Institutional Review Board (#2013-2888) as well as the Sarah Lawrence 









The sample consisted of 3,747 blood samples drawn at Montefiore Medical 
Center from January 1, 2014 to August 24, 2015 on which SNP-based NIPT was 
performed. During this time, all pregnant women were offered NIPT regardless of 
their risk for a fetal chromosome abnormality. All 3,747 samples were analyzed for 
aneuploidy on chromosomes 21, 18, 13, X and Y. 3,603 of these samples were also 
analyzed for the 22q11.2 microdeletion as it was added to reports from May 7, 2014 
onwards. 27 samples were initially excluded due to inadequate blood volume. The 
samples were then categorized by type of result: Low Risk, High Risk, Partial Result, 




were further categorized by the reason for test failure. An additional 8 samples were 
excluded due to obtaining a twin/triploidy result and/or being conceived via in-vitro 
fertilization. All women who received a high risk, partial, or no call report made up a 
cohort for which further data was collected (n = 284).  
Data Collection and Measures 
Data collected from NIPT reports included the test result, fetal fraction, 
maternal age at delivery, maternal weight, and gestational age at the time of sample 
collection. Additional information from each patient’s electronic medical record was 
gathered if available. This consisted of maternal health conditions, past and current 
pregnancy complications, ultrasound findings, prenatal screening results, diagnostic 
testing results, and pregnancy outcomes. 
For certain analyses, the cohort was divided into two sub-cohorts indicative of 
a patient’s pre-NIPT risk. High-risk a priori status is determined by a set of standards 
that varies between hospitals, but tends to include factors such as maternal age, 
medical and family history, abnormal ultrasound findings, and positive maternal 
serum screening results (Benn et al., 2013). In this study, “low a priori risk” for fetal 
aneuploidy is defined as maternal age < 35 with no reported “high risk” indications 
(ultrasound abnormalities, positive screening tests, and relevant family history). 
These criteria are consistent with those used by the NSGC and ACOG in their 








All statistical tests were performed using GraphPad InStat version 3.10 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. A P 
< 0.05 was considered statistically significant. 
Mean, median, standard deviation, and ranges were calculated for patient 
and sample characteristics. The Mann-Whitney test was used to examine 
differences in characteristics between the “low a priori risk” and “high a priori risk” 
sub-cohorts. Linear correlation analysis was used to determine the relationships 
between gestational age and fetal fraction as well as the days elapsed between 
redraws and the change in fetal fraction. 
Patient Demographics 
According to Montefiore’s 2014-2017 Community Services Plan, over 85% of 
hospital discharges are residents of Bronx County in New York State. The Bronx is 
the United States’ poorest urban county with a poverty rate of 31.5% (vs. 14.8% 
nation-wide) as well as the highest unemployment rate at 11.9% (U.S. Census 
Bureau, 2014). The 2012 U.S. Census indicated that the Bronx is ethnically diverse, 
with its population categorized as 54.3% Hispanic, 33.2% African-American, 10.6% 
White, 3.7% Asian, and 3.3% other. The health status of Montefiore’s population has 
higher than average rates of mortality, asthma, diabetes, and obesity among its 









Patient and Sample Characteristics 
The patient and sample characteristics for the 284 reviewed samples are 
detailed in Table 1. Mean maternal age at time of delivery was 31.4 years and the 
mean gestational age at sample draw was 97.1 days or 13 weeks 6 days. Only the 
first draw samples were considered in this table. Table 2 compares the mean 
maternal age, gestational age at first sample draw, maternal weight, and fetal 
fraction of the “high a priori risk” and “low a priori risk” sub-cohorts. 
Table 1: Cohort Characteristics 
Maternal Age (years) Cohort (n = 284) 
Mean 31.4±6.2 
Median 31.0 
Range 15.0 - 44.0 
Gestational Age (days)  
Mean 97.1±19.2 
Median 90.0 
Range 67.0 - 193.0 
Maternal Weight (lbs)  
Mean 193.2±54.4 
Median 181.0 
Range 92.0 - 378.0 
Fetal Fraction (%)  
Mean 5.1±3.3 
Median 3.8 









Maternal Age (years) 
Women with high a priori risk 
(n = 143) 
Women with low a priori risk  
(n = 141) 
Mean 34.8±5.8 27.6±4.1 
Median 36.0 28.0 
Range 19.0 - 44.0 15.0 - 34.0 
Gestational Age (days)   
Mean 101.3±23.4 93.1±13.0 
Median 91.0 89.0 
Range 67.0 - 193.0 67.0 - 150.0 
Maternal Weight (lbs)   
Mean 193.1±52.4 194.1±55.2 
Median 185.0 181.0 
Range 92.0 - 348.0 98.0 - 375.0 
Fetal Fraction (%)   
Mean 5.6±3.3 4.6±3.3 
Median 4.5 3.3 
Range 1.5 - 17.1 1.0 - 18.7 
For Maternal Age, the medians differed significantly (p < 0.0001). 
For Gestational Age (first draw), the medians differed significantly (p = 0.0132). 
For Maternal Weight, the medians did not differ significantly (p = 0.9516). 
For Fetal Fraction, the medians differed significantly (p = 0.0004). 
 
High Risk Results 
A breakdown of samples that received high risk NIPT results are listed in 
Table 3. Overall, 1.33% (n=48) of reports were high risk. One third (16 out of 48) of 
all high risk reports reported indicated a high risk for 22q11.2 DS. Of women who 
received a result indicating a high risk for 22q11.2 DS, 37.5% elected diagnostic 




were available were found to have an affected pregnancy. Positive predictive values 
could not be calculated due to constraints on the sample size. Table 4 summarizes 
the number of high risk NIPT results stratified by sub-cohort (high or low a priori 
risk), or the pre-NIPT risk of the patients. 




% of High 
Risk Results 








TOP SAB Term N/A 
22q11.2 DS: 16 33.33 0.44% 6 0 0 of 5* 0 0 11 5 
Monosomy 
X: 
8 16.67 0.22% 3 0 2 of 3 1 1 6 0 
Trisomy 13: 8 16.67 0.22% 6 0 2 of 6 3 0 4 2 
Trisomy 18: 6 12.50 0.17% 2 2 3 of 3* 3 3 1 0 
Trisomy 21: 5 10.42 0.14% 4 0 3 of 4 3 1 2 1 
XXY: 3 6.25 0.08% 2 0 1 of 2 1 0 1 1 
XXX: 1 2.08 0.03% 0 0 0 0 0 1 0 
XYY: 1 2.08 0.03% 0 0 0 0 0 0 1 
Total 48  1.33% 23 2 11 of 24 11 5 26 10 
* One CVS sample failed to yield a result in each of these categories.  
 
Table 4: High Risk NIPT Results Stratified by Sub-cohort 
Sub-cohort Total 
High Risk NIPT 
Results: 
22q MX T13 T18 T21 XXY XXX XYY 
% of Sub-cohort with HR 
Results 
Women with 
High a priori 
Risk 
143 33 8 7 6 6 4 1 1 0 23.08% 
Women with 
Low a priori 
Risk 
141 15 8 1 2 0 1 2 0 1 10.64% 
 
Decision Making 
The breakdown of all high risk NIPT results by pregnancy outcome and 




47.9% (n=23) elected to have a diagnostic procedure (amniocentesis or CVS), 
41.7% (n=20) declined diagnostic testing and the remaining patients experienced a 
miscarriage or intrauterine fetal demise. Over 9% (22 of 236) of patients who 
received a no call or partial result on NIPT also elected to have diagnostic testing. Of 
those with no call reports who subsequently chose diagnostic testing, 68.2% (15 
patients) had received abnormal ultrasound findings, other abnormal prenatal 
screening results (such as first trimester or quad screens), or had relevant family 
history, while 31.8% (7 patients) had not. 
Overall, 8 patients elected to terminate their pregnancies after aneuploidy 
was confirmed via diagnostic testing and 2 patients elected to terminate their 
pregnancies without confirmation via diagnostic testing. In both cases, significant 
ultrasound anomalies were present. 6 patients who received a high risk NIPT result 
and had abnormal findings on ultrasound did not opt for termination.  
No Call Samples 
Result category was determined for 3,747 samples (low risk, high risk, partial 
result, no call). The total number of no call samples was 282, or 7.53% of total 
samples. The majority of no call reports occurred on a patient’s first blood draw with 
213 (5.68%) of no call samples represented in this category.  The remaining 1.84% 
(69 samples) of no call reports occurred when the sample was a redraw on a patient 
with a previous no call or partial result report. Table 5 displays the number of no call 
reports on first draw by category as listed on the reports. Laboratory processing and 




common explanation was a low fetal fraction in combination with analytical factors, 
representing 20.66% of reports. 
 
Table 5: No Call Report Categories, Redraw Uptake, and Redraw Success Rates for No Call 
Samples 
No Call Report 
Types  (1st Draw 
only) 
Percent of Total 









   












31.92 (68) 69.12 (44/68) 88.64 (39/44) 4.55 (2/44) 6.82 (3/44) 
Low ff
c 31.92 (68) 73.53 (50/68) 10.00 (5/50) 84.00 (42/50) 6.00 (3/50) 
Low ff with analytic 
factors
d 
20.66 (44) 68.18 (30/44) 60.00 (18/30) 30.00 (9/30) 10.00 (3/30) 
Quality Metrics





0.47 (1) 00 (1/1) 100.00 (1/1) 0.00 (0/1) 0.00 (0/1) 





45.04(59/131)* 6.08 (9/131)* 
 
Results are listed as percentages with number of samples included in parentheses. a. Reported as “No results due to DNA 
pattern that cannot be interpreted by this assay. A repeat specimen is not indicated.” b. Reported as “Laboratory processing of 
this specimen could not yield results; therefore, submission of a repeat specimen is required for testing.” c. Reported as “No 
results. Fetal fraction was below the threshold for analysis.” d. Reported as “No results due to borderline low fetal fraction in 
combination with other analytic factors likely specific to this sample.”   e. Listed on the report as “Unable to report. This sample 
was processed and does not meet quality metrics” f.  Reported as “No results due to uninformative (unmatching) maternal/fetal 
DNA patterns. A repeat specimen is not indicated.” g. Success rate is determined by the number of women that received a 
result on all chromosomes being tested and 22q11.2 deletion syndrome upon redraw after receiving a no call report from their 
initial blood draw (all individuals in this category received low risk results upon redraw). h. Fail rate is determined by the 
number of women who received a no call report upon redraw after receiving a no call report from their initial blood draw. i. 
Partial rate is determined by the number of women who received a partial result upon redraw after initially receiving a no call 
report from their initial blood draw. *The DNA pattern and uninformative maternal/fetal DNA pattern categories were excluded 
from this calculation as the laboratory did not request redraw on these samples.  
 
Redraw Uptake and Success Rates 
 Uptake of NIPT redraw after receipt of a no call report on an initial blood draw 
is shown in Table 5. The overall redraw rate across all no call report types was 
67.87%.  Amongst categories for which a redraw was indicated, success was 
highest for those indicated as laboratory processing error (88.64%) and second 
highest for those indicated as low fetal fraction and analytical factors (60%). Those 




lower success rates at redraw (10% and 14.29%, respectively). Cases in which the 
initial draw failed with low fetal fraction as a contributing factor (low ff and low ff with 
analytic factors) had a redraw success rate of 28.75% (23 out of 80 women). If 
partial results are considered as successful redraws the success rate was 36.25% 
(29 out of 80 women). If only women 220 pounds or less are considered, redraw 
success rates were 37.5% (15 out of 40 women) for full results and 42.5% (17 out of 
40 women) when partial results are included.  
Redraw Samples and FF Change 
 For women who received no call reports after their initial blood draw with low 
fetal fraction indicated as a cause (categories: low fetal fraction and low fetal fraction 
with analytical factors) and chose to have a redraw, changes in fetal fraction were 
compared between the initial blood draw and the redraw as depicted in Table 6. 
 Fetal fraction increased on average by 0.564% (0.458% in the low fetal fraction 
group and 0.746% in the low fetal fraction with analytic factors group). Fetal fraction 
increased between blood draws in 67.11% of samples (51 out 76 redraws) and 
decreased in 32.89% (25 out of 76 redraws) with an average time between initial 
draw and redraw of 16.10 days.  
For all samples that had redraw data available, a significant positive 
correlation was found between the number of days from the first to second draws 
and the change in fetal fraction % (r = 0.2472, P = 0.0175). Overall, there was a 
significant positive correlation between gestational age and fetal fraction % (r = 









Table 6: Changes in Fetal Fraction between Initial Blood Draw and Redraw 
Result of 1st 
Draw 
Total # Women 
Who Elected 
Redraw 






 draw (%) 




ff between draws 








Low ff 48 +0.458 68.75 (33/48) 31.25 (15/48) 15.92 
Low ff and 
analytic factors 
28 +0.746 64.29 (18/28) 35.71 (10/28) 16.28 
Totals 76 +0.564 67.11 (51/76) 32.89 (25/76) 16.10 
a. Cases in which a woman’s fetal fraction increased from the initial draw to the redraw are considered to have a positive 
change in fetal fraction. b. Cases in which a woman’s fetal fraction decreased from the initial draw to the redraw are considered 





A significant limitation of this study is the small sample size, a reflection of the 
low prevalence rates of the conditions detected on NIPT. Moreover, many patient 
charts were incomplete, mostly due to loss of patients to follow up and missed 
appointments, which may contribute to an underestimation of prevalence rates in our 
present findings. Our sample population, as described in the Methods section, has 
higher than average rates of obesity, diabetes, and asthma. These are all 
confounding factors that may impact measures such as fetal fraction and 
accordingly, the number of no call reports seen. 
22q11.2 Deletion Syndrome Results 
This retrospective pilot study of NIPT patients in a general obstetrical 
population found that fully a third of high risk results received by Montefiore Medical 
Center were attributed to testing for 22q11.2DS. Given the low PPV of testing for 




testing were found to have false positive NIPT results. This outcome emphasizes the 
importance of thorough pre- and post-test counseling regarding not only the features 
of 22q11.2DS, but also the meaning of a high risk result for 22q11.2DS in relation to 
a high risk result for any aneuploidies on the NIPT panel. As seen here, the low 
positive predictive values of 22q11.2DS mean that many women may undergo 
diagnostic testing unnecessarily even if rates of follow-up testing remain low.  
Patients who receive high risk results for 22q11.2DS require extra care and 
attention from clinicians, since the decision to do confirmatory diagnostic testing is 
complicated by the low likelihood that the screen will be a true positive relative to 
other conditions on NIPT panel. In total, 37.5% of our patients who had a high risk 
result for 22q11.2DS elected diagnostic testing. This is in contrast to 56.67% of 
patients who elected diagnostic testing for all other high risk results or 62.96% of 
women if those who miscarried are excluded.  
It is possible that, in their decision making process, some patients weigh a 
low PPV and a “milder phenotype” versus the risks of an invasive diagnostic 
procedure and decide against confirmatory testing. The idea that women may find a 
22q11.2DS result less concerning is further supported by the decisions made by 
those who are found to have true positive results. Although none of the women in 
this study who elected diagnostic testing were found to have true positive results, a 
recent study published by Natera found that of 11 women found to be carrying a 
pregnancy affected by 22q11.2DS through microarray analysis, only 2 chose to 
terminate (Gross et. al, 2016). This may have implications regarding the clinical 





No Call Reports and Redraw Success Rates 
According to internal data published on no call reports, redraw success rates 
range from 41% for women with the lowest initial fetal fraction (<2.0%) and highest 
maternal weight (>220 lbs) to 87% for women with the highest initial fetal fraction 
that did not yield results (>3.4%) and lowest maternal weight (<165 lbs) for the 
Panorama Screen (Natera, 2015).  Other studies also report redraw success rates in 
this range (Zhou et al, 2015; Kinnings et al., 2015).  
Redraw success rates in this study for individuals with low fetal fraction and 
low fetal fraction with analytic factors on their initial NIPT report were significantly 
lower, at 28.75% for analysis of the full NIPT panel or 36.25% if partial results are 
considered as successful. One explanation for this discrepancy is that the study 
population is known to have high rates of obesity. However, if only women who 
weigh less than 220 lbs are considered from the data set, redraw success rates in 
this population still remain low at 37.5%, or 42.5% including partial results.  
Although a direct explanation cannot be provided for the low redraw success 
rate in Montefiore’s population, these results may suggest that fetal fraction and 
redraw success depend on factors other than maternal weight and gestational age. 
One study found that women of Afro-Caribbean descent had significantly lower fetal 
fractions than Caucasian women (Ashoor et al., 2013). It is possible that genetic or 
cultural factors associated with ethnicity are impacting NIPT results in this cohort of 
obstetrical patients, as nearly a third of the population that Montefiore Medical 




specific to this population as opposed to other more frequently studied cohorts would 
need to be done to understand differences in fetal fraction more completely.   
 In addition to the lower success rate, 32.89% of samples were found to have 
a negative change in fetal fraction between initial draw and redraw. Although many 
studies, including this one, have shown that fetal fraction tends to increase with 
gestational age, these studies do not look at factors affecting fetal fraction changes 
in individuals (Rava et al., 2013; Ashoor et al., 2013; Kinnings et al., 2015). At this 
point it is unclear what other factors influence changes in fetal fraction in individuals 
between blood draws. One study demonstrated that fetal fraction is lower when 
maternal blood samples are taken immediately after physical activity, but then return 
to normal at 30 minutes post-exercise (Schlütter et al., 2014). This may suggest that 
fetal fraction is more dynamic than previously thought and that many factors that 
have yet to be elucidated can impact the amount of circulating fetal DNA in maternal 
plasma. This concept is further supported by the observation that although fetal 
fraction is thought to increase by 0.1% each week of gestation (Wang et al., 2013), 
many women who receive no call reports on an initial blood draw are able to obtain 
results upon redraw within a few weeks even if their original fetal fraction was well 
below the threshold for analysis. 
Further research examining characteristics of women who showed a 
decrease in fetal fraction between draws compared with those who showed an 
increase in fetal fraction is needed. With increased understanding of this topic, it 
may be possible to determine which factors influence whether fetal fraction will 




to patients who receive a no call report. In addition, since recent studies have 
reported that low fetal fraction is associated with an increased risk for aneuploidy 
(Ashoor et al, 2013; Palomaki et al., 2015), a better understanding of what other 
factors can cause low fetal fraction could help to elucidate women at a higher risk 
after a result indicating low fetal fraction.  
Post-test Counseling Challenges 
The observation that over 9% of patients who received a no call or partial 
result chose to proceed with diagnostic testing suggests that the uncertainty of NIPT 
results may increase maternal anxiety. Certain factors causing a no call report, such 
as a low fetal fraction, have been linked to an increased risk for aneuploidy 
(Pergament et al., 2014). A redraw is typically offered in such cases, but it raises the 
question of whether or not patients should be counseled on the probability of a 
successful redraw as well as the potential implications of a delayed diagnosis. For 
these cases, it will be of the utmost importance to emphasize the recommendations 
of the American Congress of Obstetricians and Gynecologists (ACOG) in offering 
comprehensive ultrasound evaluation and diagnostic testing.  
The significant number of 22q11.2DS and no call cases in this population 
means that detailed post-test counseling is required for many patients. Given the 
current shortage of genetic counselors and other clinicians who are able to provide 
genetic counseling, offering NIPT to the general population and including 
microdeletion syndromes could have a large impact on the field. It is possible that 




confirmatory testing, which is especially concerning in the context of the low PPVs of 
microdeletion syndromes.  
Current ACOG guidelines regarding cell-free DNA screening advise against 
routine screening for microdeletion syndromes. It will be important for the ordering 
clinician to distinguish between the standard NIPT panel for aneuploidies versus an 
expanded panel that includes microdeletion syndromes when determining the 
appropriate panel for their patient. The NSGC, ACMG, and ACOG all recommend 
thorough patient education which includes pre- and post-test counseling for all NIPT 
patients. This issue has the potential to be exacerbated in the coming years, as 
offering NIPT to the general population will greatly increase demands on current 




This pilot study sets the stage for future research into NIPT utility, especially 
with regards to 22q11.2DS. It would be beneficial to obtain follow up data on women 
who receive high risk results as well as educating women about 22q11.2DS and 
surveying them to determine how recieving these results would impact decision 
making regarding their pregnancies. Additionally, a data set from a larger sample 
size that includes ethnic background and socioeconomic information would provide 
insight into any differences between populations. Qualitative research such as focus 
groups or interviews may reveal important facts about a particular population and its 
attitudes towards NIPT. These findings will be important for clinicians serving similar 




It would also be helpful to further examine differences in fetal fraction 
changes across women of various ethnic backgrounds and socioeconomic classes. 
To help elucidate what factors affect fetal fraction, women could be given surveys 
immediately preceding blood draws for NIPT to observe characteristics such as diet, 
sleep, exercise, time of day, and maternal conditions. It would also be important to 
determine if fetal fraction levels are variable throughout a pregnancy despite a net 
increase with gestational age. This information could aid in providing more accurate 
risk assessments and redraw success rates for women who receive no call reports.  
Although the implementation of NIPT as a screening tool in the general 
population has increased accuracy compared to traditional screening methods, this 
new technology has also presented challenges in practice.  Adding additional 
conditions such as 22q11.2DS to NIPT panels will affect pre and post-test 
counseling and complicate patient decision making. Overall, our study suggests 
patients need to be aware that NIPT does not replace diagnostic testing, that PPVs 
differ significantly for microdeletion syndromes, and that redraw success is variable. 
Additionally, understanding the dynamics of NIPT including no call reports and how 
the reason for a no call report may influence the likelihood of a successful redraw, 
and the relationship between fetal fraction and outcome data on the pregnancy and 
the fetus, may improve how NIPT is used on an individual level. Differences in the 
characteristics of the population being offered NIPT, including prior risk for 
aneuploidy, maternal characteristics such as weight, and attitudes toward diagnostic 
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